Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective The Vienna Challenge Chamber (VCC) offers a controlled and controllable paradigm in which to reproducibly evaluate the efficacy of anti-allergic treatment. The aim of this study was to assess the efficacy of the novel intranasal corticosteroid fluticasone furoate (FF) in the VCC. Methods The single-centre, randomised, double-blind, placebo-controlled, two-period crossover study was conducted in 59 adult males with grass pollen allergic rhinitis (AR). Patients received either Fluticasone furoate 200 mcg once-daily, or placebo intranasally for 8 days. AR symptoms were induced during 4-hour allergen challenges with grass pollen in the VCC at the end of each 8-day treatment period. A first challenge was conducted at 1-5 hours post-dose, followed by a second challenge at 22-26 hours post-dose. The primary endpoint was total nasal symptom score (TNSS; sum of itch, sneeze, rhinorrhoea, obstruction symptoms assessed on a categorical scale of 0-3) weighted mean over 2-5 hours post-dose. Secondary endpoints included: TNSS weighted mean over 23-26 hours post-dose and global symptom score, eye symptom score, nasal secretions and nasal airflow weighted means over 2-5 and 23-26 hours post-dose. Results Fluticasone furoate showed consistent attenuation of AR symptoms in both the early and late challenges. Compared with placebo, weighted mean of TNSS was reduced on average by 4.14 point-scores at 2-5 hours post-dose and 3.63 point scores at 23-26 hours post-dose. These positive eff…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this respect, numerous randomized, placebo-controlled clinical trials have been conducted using parallel-group or crossover designs in order to test the efficacy of drugs with immediate therapeutic activity, such as antihistamines,1050-1053 or with prophylactic therapeutic potential, such as topical steroids,1054-1056 novel anti-inflammatory compounds,1057-1060 or probiotics.1061”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1056]
Citations
Cites
The human pharmacology of fluticasone propionate
Harding, S. M. (1990) · Respiratory Medicine · doi:10.1016/s0954-6111(08)80004-2 · Cited by 313 · cited 1×
“A patient was eligible for inclusion in this study only if all of the following criteria applied: (1) male (there were insufficient data on reproduction toxicology at the time of the study to permit the inclusion of females); (2) healthy (defined as free from clinically significant illness or disease as determined by…”
Horak, F., Stübner, U. P., Zieglmayer, R., & Harris, A. G. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.124657 · Cited by 111
Self-citationHorak, F., Petra Zieglmayer, U., Zieglmayer, R., Kavina, A., Marschall, K., Munzel, U., & Petzold, U. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80305 · Cited by 98
Self-citationImmunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study.
Horak, F., Stübner, P., Berger, U. E., Marks, B., Toth, J., & Jäger, S. (1998) · PubMed · Cited by 92
Self-citationMartin, B. G., Ratner, P. H., Hampel, F. C., Andrews, C. P., Toler, T., Wu, W., Faris, M. A., & Philpot, E. E. (2007) · Allergy and Asthma Proceedings · doi:10.2500/aap.2007.28.2983 · Cited by 78 · cited 1×
“A patient was eligible for inclusion in this study only if all of the following criteria applied: (1) male (there were insufficient data on reproduction toxicology at the time of the study to permit the inclusion of females); (2) healthy (defined as free from clinically significant illness or disease as determined by…”
Horak, F., Stübner, P., Zieglmayer, R., Kavina, A., De Vos, C., Burtin, B., & Donnelly, F. (2001) · International Archives of Allergy and Immunology · doi:10.1159/000053799 · Cited by 66
Self-citationStübner, P., Zieglmayer, R., & Horak, F. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003700 · Cited by 62
Self-citationDay, J. H., Horak, F., Briscoe, M. P., Canonica, G. W., Fineman, S. M., Krug, N., Leynadier, F., Lieberman, P., Quirce, S., Takenaka, H., et al. (2006) · Clinical & Experimental Allergy Reviews · doi:10.1111/j.1365-2222.2005.00099.x · Cited by 57 · cited 1×
“A patient was eligible for inclusion in this study only if all of the following criteria applied: (1) male (there were insufficient data on reproduction toxicology at the time of the study to permit the inclusion of females); (2) healthy (defined as free from clinically significant illness or disease as determined by…”
Self-citationDay, J. H., Briscoe, M. P., Rafeiro, E., Chapman, D. S., & Krämer, B. (2001) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)62260-0 · Cited by 56 · cited 1×
“A patient was eligible for inclusion in this study only if all of the following criteria applied: (1) male (there were insufficient data on reproduction toxicology at the time of the study to permit the inclusion of females); (2) healthy (defined as free from clinically significant illness or disease as determined by…”
Horak, F., Stübner, P., Zieglmeyer, R., & Harris, A. G. (2003) · Allergy · doi:10.1034/j.1398-9995.2003.00148.x · Cited by 54
Self-citation
Research works printed but not linked: 5
- Horak F, 1987, Wien Klin Wochenschr, 99, 509
- Horak F, 2005, Ann Allergy Asthma Immunol, 94, 104
- Horak F, 2004, Drug Res, 54, 666
- Horak F, 2000, Drug Research, 50, 1099
- Horak F, 1998, J Investig Allergol Clin Immunol, 8, 165
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Devillier, P., Montagut, A., Mélac, M., Galvain, S., Jean-Alphonse, S., Van Overtvelt, L., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.006 · Cited by 175
Self-citationNolte, H., Maloney, J., Nelson, H. S., Bernstein, D. I., Lu, S., Li, Z., Kaur, A., Zieglmayer, P., Zieglmayer, R., Lemell, P., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1911 · Cited by 160
Self-citationARIA guideline 2019: treatment of allergic rhinitis in the German health system
Klimek, L., Bachert, C., Pfaar, O., Becker, S., Bieber, T. R. M., Brehler, R., Buhl, R., Casper, I., Chaker, A. M., Czech, W., et al. (2019) · Allergologie · doi:10.5414/alx02120 · Cited by 150
ARIA guideline 2019: treatment of allergic rhinitis in the German health system
Klimek, L., Bachert, C., Pfaar, O., Becker, S., Bieber, T. R. M., Brehler, R., Buhl, R., Casper, I., Chaker, A. M., Czech, W., et al. (2019) · Allergo Journal International · doi:10.1007/s40629-019-00110-9 · Cited by 90
Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J., Lewis, T., Payton, M. A., Perkins, C. M., et al. (2012) · Allergy · doi:10.1111/all.12042 · Cited by 85
Self-citationDevillier, P., Le Gall, M., & Horak, F. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02473.x · Cited by 58
Self-citationTechnical standards in allergen exposure chambers worldwide – an EAACI Task Force Report
Pfaar, O., Bergmann, K., Bonini, S., Compalati, E., Domis, N., de Blay, F., de Kam, P., Devillier, P., Durham, S. R., Ellis, A. K., et al. (2021) · Allergy · doi:10.1111/all.14957 · Cited by 39
“Reproducibility and consistency have been proven (42-44).”
Self-citationThe effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis
Bareille, P., Murdoch, R. D., Denyer, J., Bentley, J., Smart, K., Yarnall, K., Zieglmayer, P., Zieglmayer, R., Lemell, P., & Horak, F. (2013) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201890 · Cited by 41
“Despite treatment, many patients may still suffer some residual symptoms [9, 10], and it has been reported that up to 1 in 5 patients with AR remain symptomatic when treated with the best available pharmacotherapy [11].”
BackgroundSelf-citationRogóż, K., Andersen, H. H., Kullander, K., & Lagerström, M. C. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.089532 · Cited by 37
Horak, F., Puri, K. D., Steiner, B. H., Holes, L. M., Xing, G., Zieglmayer, P. U., Zieglmayer, R., Lemell, P., & Yu, A. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1313 · Cited by 35
Self-citationNorth, M. L., Soliman, M., Walker, T., Steacy, L. M., & Ellis, A. K. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0514-4 · Cited by 30
Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis
Badorrek, P., Hohlfeld, J. M., Krug, N., Joshi, A., & Raut, A. (2015) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2015.07.016 · Cited by 28
New Therapies for Allergic Rhinitis
Braido, F., Sclifò, F., Ferrando, M., & Canonica, G. W. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0422-z · Cited by 27
2019 ARIA: care pathways for allergic rhinitis in Russia
Khaitov, M. R., Namazova-Baranova, L. S., Ilyina, N. I., Kurbacheva, O. M., Bachert, C., Hellings, P. W., Pfaar, O., Schünemann, H. J., Wallace, D. V., Bedbrook, A., et al. (2020) · Russian Journal of Allergy · doi:10.36691/raj.2020.17.1.001 · Cited by 23
A review of the use of fluticasone furoate since its launch
Villa, E., Magnoni, M. S., Micheli, D., & Canonica, G. W. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.600688 · Cited by 22
“Importantly, its 24-h efficacy supported FF as a once-daily effective steroid [38].”
BackgroundMurdoch, R. D., Bareille, P. J., Ignar, D. M., Miller, S. R., Gupta, A., Boardley, R., Zieglmayer, P. U., Zieglmayer, R., Lemell, P., & Horak, F. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12556 · Cited by 21
Self-citationAllergic rhinitis.Clinical practice guidelines.
Pavlova, K. S. (2022) · Russian Journal of Allergy · doi:10.36691/rja1524 · Cited by 12
ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem
Klimek, L., Bachert, C., Pfaar, O., Becker, S., Bieber, T. R. M., Brehler, R., Buhl, R., Casper, I., Chaker, A. M., Czech, W., et al. (2019) · Allergo Journal · doi:10.1007/s15007-019-1938-2 · Cited by 11
Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit
Ellis, A. K., Steacy, L. M., Joshi, A., Bhowmik, S., & Raut, A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.07.018 · Cited by 9
2019 ARIA Care Pathways for Allergic Rhinitis-Turkey
YORGANCIOGLU, A. A., Gemicioğlu, B., Cingi, C., Kalaycı, Ö., Kalyoncu, A. F., Bachert, C., Hellings, P. W., Pfaar, O., Schünemann, H. J., Wallace, D. V., et al. (2019) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2019.19084 · Cited by 8
Novel, Alternative, and Controversial Therapies of Rhinitis
Šurda, P., & Fokkens, W. J. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.12.014 · Cited by 8
Hossenbaccus, L., Steacy, L. M., Walker, T., & Ellis, A. K. (2020) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00922-8 · Cited by 8
ARIA 2019: Um Percurso Assistencial Integrado para a Rinite Alérgica em Portugal
Fonseca, J., Taveira‐Gomes, T., Pereira, A. M., Ferreira, M. B., Martins, P., Alves‐Correia, M., de Sousa, J. C., Costa, E. M., Lourenço, O. M., Morais‐Almeida, M., et al. (2020) · Acta Médica Portuguesa · doi:10.20344/amp.13777 · Cited by 8
2019 ARIA – Care pathways for allergic rhinitis – Poland
Samolinski, B. K., Krzych‐Fałta, E., Piekarska, B., Lipiec, A., Kuna, P., Kupczyk, M., Jutel, M., Niedoszytko, M., Jassem, E., Kowalski, M. L., et al. (2019) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2019.91214 · Cited by 6
Current Clinical Guidelines for the Management of Patients with Allergic Rhinitis
Astaf’eva, N. G., Aa, B., Vishneva, Е. A., Daykhes, N. A., Zhestkov, A. V., Ивановна, И. Н., Витальевна, К. О., Karpova, E. P., Kim, I. A., Kryukov, A. I., et al. (2024) · Педиатрическая фармакология · doi:10.15690/pf.v21i4.2774 · Cited by 4
Ivancevich, J. C., Cardona, V., Larenas‐Linnemann, D. E., Mullol, J., Neffen, H. E., Zernotti, M. E., Asayag, E., Blua, A. E., Gómez, R. M., Jares, E. J., et al. (2019) · Revista Alergia México · doi:10.29262/ram.v66i4.643 · Cited by 4
ПРОЕКТ “ARIA”: ШЛЯХИ НАДАННЯ МЕДИЧНОЇ ДОПОМОГИ ПРИ АЛЕРГІЧНОМУ РИНІТІ (2019 РІК) – УКРАЇНА
Gogunska, I. V., Zabolotna, D. D., Зайков, С. В., Кайдашев, І. П., Уманец, Т. Р., Чоп’як, В., Яшина, Л. Л., Бахерт, С., Hellings, P. W., Pfaar, O., et al. (2019) · The Medical and Ecological Problems · doi:10.31718/mep.2019.23.5-6.01 · Cited by 3
DuBuske, L. M. (2012) · American Journal of Rhinology and Allergy · doi:10.2500/ajra.2012.26.3770 · Cited by 2
Hashiguchi, K., Kanzaki, S., Wakabayashi, K., Tanaka, N., Kawashima, K., Suematsu, K., Tokunaga, S., Ogawa, K., & Okubo, K. (2013) · Journal of Drug Assessment · doi:10.3109/21556660.2013.829070 · Cited by 2
“An exposure chamber trial conducted by Zieglmayer et al.35 in the VCC evaluated the efficacy of a 1-week treatment with high-dose (200mg) FFNS in grass-pollen sensitized 102 Combination therapy with fluticasone furoate and levocetirizine Hashiguchi et al. www.informahealthcare.com/JDA !”
MethodKraxner, H., Hirschberg, A., & Nékám, K. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.31919 · Cited by 2
Mahboub, B., El-Hefny, Y., Fraihat, A., Persaud, R., Juratli, A., Tadros, F. A., Aljassim, A., Hantzakos, A. G., Hoffmann, B., Alabdali, K., et al. (2022) · New Emirates Medical Journal · doi:10.2174/03666220913105943 · Cited by 2
Efficacité des corticoïdes par voie nasale sur les symptômes oculaires de la rhinite allergique
Demoly, P. M., Klossek, J. M., Serrano, É., & Didier, A. P. (2010) · Revue française d'allergologie · doi:10.1016/j.reval.2010.03.002 · Cited by 1
2019 ARIA Care pathways for allergic rhinitis – Egypt
El‐Gamal, Y., El-Owaidy, R. H., El-Sayed, S. S., El-Sayed, Z., Hossny, E. M., Reda, S. M., Bachert, C., Fokkens, W. J., Haahtela, T., Hellings, P. W., et al. (2020) · The Egyptian Journal of Pediatric Allergy and Immunology · doi:10.21608/ejpa.2020.81763
Identification, caractérisation et validation de biomarqueurs liés à l’immunothérapie allergénique
Caillot, N. (2015) · theses.fr (ABES) · doi:10.70675/98f70acdz10e3z41fez8434zc21404ec5613
Metadata
- Authors
- Zieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F.
- Affiliations
- Vienna Challenge Chamber (AT)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Zieglmayer, Petra
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2008-05-28
- Volume
- 24
- Issue
- 6
- Pages
- 1833-1840
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2158466843
- Cited by
- 35
- References
- 19
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 7 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 2
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- fluticasone furoate, allergic rhinitis, grass pollen allergy, intranasal corticosteroids, allergen challenge, nasal symptom score, ocular symptoms, rhinorrhea, nasal obstruction
- MeSH terms
- Adolescent, Adult, Androstadienes, Double-Blind Method, Environmental Exposure, Glucocorticoids, Poaceae, Rhinitis, Allergic, Seasonal, Humans, Male, Middle Aged, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.